Method for preparing organoid using stem cell self-organizing ability and organoid prepared by same method

MYPI2025002184A0Undetermined Publication Date: 2024-04-12CELLINCELLS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002184
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-12
Filing Date
2023-10-10
Publication Date
2024-04-12

AI Technical Summary

Technical Problem

Current methods for producing organoids face limitations in size due to insufficient nutrient and oxygen supply to the center, leading to structural size constraints and challenges in maintaining cell composition over long culture times, especially when using artificial scaffolds that fail to replicate the extracellular matrix effectively.

Method used

A method utilizing the self-assembly and self-structuring ability of mesenchymal stem cells to form cup-shaped organoid-tissue modules by mixing and culturing spheroids of varying sizes, eliminating the need for artificial scaffolds and ensuring adequate nutrient and oxygen supply to the central region, thereby enabling the production of millimeter-sized organoids.

Benefits of technology

This approach allows for the production of large-sized organoids with improved nutrient and oxygen supply, maintaining stem cell characteristics, and demonstrating effective cartilage regeneration capabilities, including successful transplantation into damaged joints.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025002184_DRAWING_001
    Figure PI2025002184_DRAWING_001
  • Figure PI2025002184_DRAWING_002
    Figure PI2025002184_DRAWING_002
  • Figure PI2025002184_DRAWING_003
    Figure PI2025002184_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to a novel method for preparing an organoid using the self-assembly of spheroid. Particularly, the organoid prepared by the preparation method of the present invention has a cup-shaped morphology with a concave center, and thus, the following advantages may be obtained: nutrients and oxygen can be smoothly supplied to the center; and limitations in the size of organoid can be overcome. FIGURE 1
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing organoids using stem cell self-organization ability and organoids produced by the method

[0001] The present invention relates to a novel method for manufacturing organoid-tissue modules using the self-assembly of spheroids, and to organoid-tissue modules manufactured by the method. Specifically, the organoid-tissue modules manufactured by the manufacturing method of the present invention have a cup-shaped shape with a concave center, thereby enabling a smooth supply of nutrients and oxygen to the center and overcoming limitations in organoid size.

[0002]

[0003] Tissue engineering aims to restore or improve the function of organs or tissues by developing functional substitutes for damaged tissues (Griffith & Naughton, 2002; Langer & Vacanti, 1993). To develop these functional substitutes, research on organoids, which can mimic human organ tissues, is crucial. Stem cell culture using 3D culture methods leads to the formation of organoids, 3D cell aggregates composed of multiple cells through self-renewal and self-organization (Kaushiket et al., 2018). Because these organoids can mimic the structural and functional properties of living tissue, they can be used not only for tissue regeneration therapies but also as miniaturized organ models for personalized disease modeling and drug screening (Kaushiket et al., 2018).

[0004] Embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells (ASCs) are used as cell sources for organoids. In particular, mesenchymal stem cells (MSCs), a type of adult stem cell, are attracting attention as a cell source for organoids because they can be easily isolated and cultured from various adult tissues such as bone marrow and adipose tissue (Jianget et al., 2002; Pittenger et al., 1999; Wang et al., 2014). To culture these stem cells in three dimensions, a structural support similar to an extracellular matrix (ECM) is required. Matrigel is the most commonly used scaffold, but its composition has not been fully characterized and it contains several growth factors that are difficult to quantify, making it difficult to consistently control the cell environment each time an organoid is cultured. Alternatively, three-dimensional synthetic scaffolds can be used using biomaterials such as hydrogels and polyethylene glycol. However, these scaffolds have the disadvantage of not being able to perfectly reproduce the extracellular matrix of biological tissues (Hofer & Lutolf, 2021; Khademhosseini & Langer, 2016). Therefore, there is a growing demand for organoid production without the aid of scaffolds.

[0005] Embryology-based tissue engineering seeks to overcome this dependence on artificial scaffolds by leveraging the ability of cells to synthesize their own extracellular matrix under specific conditions (Burdis & Kelly, 2021). When cells attach to their own synthesized extracellular matrix, they can engage in cell-cell and cell-extracellular matrix interactions that more closely resemble those of native tissue. These interactions trigger biological processes such as self-assembly and self-organization. Self-assembly and self-organization can be induced through cell aggregation technologies. Most cell aggregation technologies rely on external physical forces, such as centrifugal force and electromagnetic fields, and most are spherical in structure. Spherical organoids produced by these technologies are inherently limited in size due to insufficient oxygen and nutrients reaching the center. Consequently, long-term culture times are required to obtain large organoids, and increased culture times make it difficult to control the cellular composition of the organoids.

[0006] Accordingly, in order to solve the above problems, the inventors of the present invention developed a method for producing organoids that are not limited in size through the self-assembly and self-structuring ability of stem cells, and completed the present invention by isolating human mesenchymal stem cells (hMSCs) from human fat, culturing them in two dimensions, and producing millimeter-sized organoid-tissue modules composed of mesenchymal stem cells using a tertiary culture technique.

[0007] Through this, the inventors of the present invention confirmed that by producing millimeter-sized cup-shaped cartilage organoids in a chondrocyte differentiation environment and transplanting the organoids into the cartilage of damaged joints, they had the effect of cartilage regeneration.

[0008]

[0009] The present invention provides a method for producing organoids several millimeters in size by mixing and culturing spheroids of different sizes and utilizing the self-assembly ability of the spheroids. The method simplifies complex organoid production methods and provides organoids with a cup-shaped structure capable of supplying nutrients and oxygen to the central region.

[0010]

[0011] In order to achieve the above-described purpose, the present invention provides a method for producing an organoid-tissue module by mixing and culturing spheroids of different diameters.

[0012] In addition, the present invention provides an organoid-tissue module manufactured by the above manufacturing method.

[0013] In addition, the present invention provides a pharmaceutical composition for preventing or treating cartilage disease, comprising an organoid-tissue module manufactured by the above manufacturing method.

[0014] In the above manufacturing method, the spheroid may be characterized as having a diameter of 10 to 1,000 μm, and preferably a diameter of 50 to 500 μm.

[0015] In the above manufacturing method, spheroids having a diameter of 200 μm or less may be 60% or more of the total spheroids, preferably 70% or more, and more preferably 80% or more.

[0016] Additionally, in the above manufacturing method, spheroids having a diameter exceeding 200 μm may be 40% or less of the total spheroids, preferably 30% or less, and more preferably 20% or less.

[0017] Additionally, in the above manufacturing method, the number of spheroids having a diameter of 200 μm or less may be greater than the number of spheroids having a diameter of more than 200 μm.

[0018] Additionally, in the above manufacturing method, the occupied space of a spheroid having a diameter of 200 μm or less may be larger than the occupied space of a spheroid having a diameter of more than 200 μm.

[0019] Additionally, in the above manufacturing method, the space not occupied by the spheroids may be 5 to 40% of the total space for culturing the spheroids, preferably, the space not occupied by the spheroids may be 10 to 35% of the total space for culturing the spheroids, and more preferably, the space may be 15 to 30% of the total space.

[0020] Additionally, in the above manufacturing method, the organoid-tissue module may occupy 10 to 35% of the culture area, and the organoid-tissue module may have an average diameter of 2 to 4 mm.

[0021] In addition, in the above manufacturing method, the spheroid can be obtained by culturing stem cells or undifferentiated cells, and preferably, the stem cells and undifferentiated cells can be selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, adult stem cells, and mesenchymal stem cells, and more preferably, the stem cells can be human adipose-derived mesenchymal stem cells (hMSCs).

[0022] Additionally, in the above manufacturing method, the organoid-tissue module may have a cup-shaped shape.

[0023] Additionally, the above manufacturing method may not include a scaffold and artificial materials.

[0024]

[0025] The present invention provides a technology for manufacturing organoid-tissue modules and tissue complexes free from scaffolds and xenografts. Organoid-tissue modules manufactured using the manufacturing method of the present invention have a cup-shaped form, eliminating the problems of oxygen and nutrient supply. Furthermore, the self-assembly ability of spheroids allows for easy manufacturing of organoid-tissue modules within a short period of time.

[0026] In addition, organoids manufactured using the manufacturing method of the present invention maintain the characteristics of stem cells and can be used to treat various diseases, including cartilage diseases.

[0027]

[0028] Figure 1 is a schematic diagram showing the principle of the technology for producing organoid-tissue modules (TM).

[0029] Figure 2 is a photograph and graph showing the morphology of human mesenchymal stem cells (hMSCs) and their cell division ability according to subculture.

[0030] Figure 3 is a graph showing the stem cell surface positive marker of hMSCs using FACS.

[0031] Figure 4 is a graph showing the stem cell surface negative marker of hMSCs using FACS.

[0032] Figure 5 is a photograph confirming through a microscope that hMSCs have differentiation properties.

[0033] Figure 6 is a photograph of a spheroid mixture that failed to generate organoid-tissue modules.

[0034] Figure 7 is a photograph of a spheroid mixture that successfully generated organoid-tissue modules.

[0035] Figure 8 is a schematic diagram and hourly photographs of a time-lapse video recording the process of organoid-tissue module formation over 72 hours.

[0036] Figure 9 is a photograph showing the process of smaller spheroids being attracted and fused around a larger spheroid during the formation of an organoid-tissue module.

[0037] Figure 10 is a graph showing the size distribution of spheroids produced for the production of organoid-tissue modules.

[0038] Figure 11 is a graph showing the average diameter of spheroids belonging to each range after classifying them by size of 200 μm or less and size exceeding 200 μm among the spheroid mixtures that successfully produced organoid-tissue modules for successful organoid-tissue module production.

[0039] Figure 12 is a graph showing the distribution of the number of spheroids according to the size of mixed spheroids produced with organoid-tissue modules and mixed spheroids that were not produced.

[0040] Figure 13 is a graph showing the distribution of spheroid occupancy space according to the size of mixed spheroids produced with organoid-tissue modules and mixed spheroids that were not produced.

[0041] Figure 14 is a graph showing the distribution of empty space not occupied by mixed spheroids produced with organoid-tissue modules and mixed spheroids that were not produced.

[0042] Figure 15 is a graph showing the average movement speed of spheroids over time during the process of forming organoid-tissue modules according to self-organization.

[0043] Figure 16 is a graph showing the deviation in the movement distance and average speed of spheroids over time during the process of forming organoid-tissue modules according to self-organization ability.

[0044] Figure 17 is a graph showing the trajectory of a spheroid during the process of forming an organoid-tissue module according to self-organization.

[0045] Figure 18 is a graph showing the circularity according to the stage of organoid-tissue module formation, the speed over time, and the time to reach the initiation, condensation, lifting, and folding stages.

[0046] Figure 19 is a photograph and graph showing that the size of spheroids changes when the number of cells is adjusted.

[0047] Figure 20 is a photograph showing the effect of the mixing ratio of two types of spheroids of different sizes on the formation of organoid-tissue modules.

[0048] Figure 21 is a photograph showing the presence or absence of organoid-tissue module creation according to the ratio of the area not occupied by mixed spheroids in the total culture area.

[0049] Figure 22 is a photograph showing the self-structuring and maintenance of the cup-shaped morphology of organoid-tissue modules produced with two types of spheroids of different sizes.

[0050] Figure 23 is a photograph showing the process of fusion of two types of spheroids of different sizes.

[0051] Figure 24 is a photograph of a fluorescently stained organoid-tissue module taken using a confocal microscope.

[0052] Figure 25 is a photograph and graph showing the results of confirming stem cell markers and differentiation potential of cells isolated from organoid-tissue modules.

[0053] Figure 26 is a photograph and graph showing the results of comparing the organoid-tissue module with spherical cell aggregates to demonstrate that the organoid-tissue module is resistant to apoptosis.

[0054] Figure 27 is a photograph showing the expression and location of type Ⅱ collagen in organoid-tissue modules that induced cartilage differentiation as confirmed through immunohistological staining.

[0055] Figure 28 is a photograph and graph showing the distribution of nuclei stained with Aggrecan expression and SYTO16 by 3D clearing of organoid-tissue modules that induced cartilage differentiation.

[0056] Figure 29 is a graph showing the content of glycosaminoglycan (GAG), a cartilage extracellular matrix, in organoid-tissue modules in which cartilage differentiation was induced.

[0057] Figure 30 is a photograph showing the results of histological analysis using various staining techniques applied to organoid-tissue modules that induced cartilage differentiation.

[0058] Figure 31 is a photograph showing the efficacy and histological analysis results of transplantation of organoid-tissue modules that induced cartilage differentiation into rabbit cartilage.

[0059]

[0060] Hereinafter, with reference to the attached drawings, embodiments and examples of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various forms and is not limited to the embodiments and examples described herein.

[0061] Throughout this specification, whenever a part is said to “include” a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise stated.

[0062] The method for manufacturing an organoid-tissue module of the present invention comprises the first step of isolating mesenchymal stem cells (hMSCs) from human fat, culturing them in two dimensions, and producing spheroids using three-dimensional culture technology, and the second step of mixing and culturing spheroids of various sizes to produce an organoid-tissue module, which is a cup-shaped organoid.

[0063] A schematic diagram of the present invention for producing organoids of several millimeters in size from a single cell is shown in Fig. 1.

[0064] The above “two-dimensional culture” means culturing cells in a monolayer in any type of culture vessel, such as a cell culture flask or flat petri dish.

[0065] The above "3D culture" is a culture in which cells interact with all three dimensions surrounding them, and has the characteristic of allowing cells to grow in all directions.

[0066] The above "organoid" refers to a tissue mimic that is a three-dimensional culture of stem cells that has a form similar to actual human tissues and organs through self-structuring.

[0067] The above “organoid-tissue module (Tissue Module, TM)” refers to an organoid that has not differentiated into a specific organ tissue and is produced through self-structuring of a spheroid.

[0068] The above “cup shape” refers to a shape having a concave groove in the middle.

[0069] In the present invention, “stem cells” include adult stem cells, preferably “mesenchymal stem cells,” and more preferably “human adipose-derived mesenchymal stem cells.”

[0070] The present invention will be described in more detail through the following examples; however, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[0071]

[0072] [Example 1]

[0073] Isolation of mesenchymal stem cells (hMSCs) from adipose tissue

[0074]

[0075] Human adipose-derived mesenchymal stem cells (hMSCs), which are relatively easy to isolate and have a high growth rate, were used as the cell source for the production of the organoid-tissue module of the present invention (Meligy et al., 2012). The isolation of hMSCs was performed with approval from the Institutional Review Board of Seoul National University Dental Hospital.

[0076] The prepared human adipose tissue was placed in Hanks® Balanced Salt solution (HBSS) containing 0.1% collagenase I and shaken at 37°C for 30 minutes to separate the cells, which were then washed and filtered through a 100 μm nylon mesh. Afterwards, the cells were supplied with nutrients from Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1X antibiotic-antimycotic solution (AA) and cultured in a 5% CO2 incubator at 37°C.

[0077]

[0078] [Example 2]

[0079] Validation of isolated mesenchymal stem cells (hMSCs)

[0080]

[0081] The hMSCs isolated as described above have characteristics such as adherent morphology, multipotency, and expression of surface-specific antigens (Dominici et al., 2006), and by confirming these characteristics, it was verified that the cells isolated in Example 1 were hMSCs.

[0082] As a result of confirming the morphology and distribution characteristics of the above cells, as shown in Fig. 2, the cells showed a homogeneous spindle-like shape attached and growing on a plastic culture dish, and the period required for the number of cells to double was maintained at a constant 2 days from the 2nd passage to the 12th passage.

[0083] In addition, to confirm that the characteristics of hMSCs are well maintained through repeated passages, the expression of stem cell surface markers was confirmed through fluorescence. At passages 3, 5, and 7, the cells were reacted with antibodies against fluorescently labeled CD14, CD29, CD31, CD34, CD44, CD73, CD90, HLA-DR, CD45, CD79α, CD105, and CD117 for 1 hour at 4°C. Afterwards, the cells were washed using Dulbecco's phosphate-buffered saline (DPBS) containing 2% FBS, and the expression level compared to the isotype mouse IgG control was analyzed by FACS.

[0084] As a result of the test, more than 95% of the cells expressed positive markers of CD29, CD44, CD73, CD90, and CD105 as shown in Figure 3, and the expression of negative markers of CD14, CD31, CD45, CD79α, CD117, and HLA-DR was confirmed to be less than 2% as shown in Figure 4.

[0085]

[0086] [Example 3]

[0087] Confirmation of osteogenic differentiation potential of isolated mesenchymal stem cells (hMSCs)

[0088]

[0089] To confirm the osteogenic differentiation potential of hMSCs, 9.5x10 4The cells were placed in 6-well plates and cultured in culture medium prepared by adding 10 nM dexamethasone, 50 μg / mL ascorbic acid, 10 mM β-glycerolphosphate, 1 mM dibutyryl-cAMP, 10% FBS, and 1X AA to alpha minimum essential medium (α MEM). After 4 days, the culture medium was completely removed and replaced with medium without dibutyryl-cAMP twice a week, and cultured in a 5% CO2 incubator at 37°C for 14 days to induce differentiation of hMSCs into osteocytes.

[0090] Afterwards, alizarin red S staining was performed to visually confirm osteocyte differentiation. The culture medium of the plate where differentiation was completed was removed and washed once with DPBS, and 1 mL of 4% paraformaldehyde (PFA) was added and the cells were fixed at room temperature. The fixative was removed and washed with DPBS, and 2 mL of alizarin red S solution diluted to 1% using distilled water (DW) was dispensed and reacted at room temperature for 15 minutes. After washing five times with DW and dispensing 1 mL of DW, osteocyte differentiation (osteogenic differentiation) was confirmed under a microscope (Olympus), as shown in Figure 5.

[0091]

[0092] [Example 4]

[0093] Confirmation of the adipocyte differentiation potential of isolated mesenchymal stem cells (hMSCs)

[0094]

[0095] In order to confirm the adipocyte differentiation ability, 9.5x10 4The cells were placed in 6-well plates and cultured in a culture medium containing 0.5 mM isobutylmethylxanthine (3-isobutyl-1-methylxanthine, IBMX), 100 nM dexamethasone, 100 μM indomethacin (INDO), 10 μg / mL insulin, 10% FBS, and 1X AA in high glucose DMEM for 14 days in a 5% CO2 incubator at 37°C, with the medium replaced twice a week. To confirm differentiation, the culture medium from the plates where differentiation was complete was removed, washed once with DPBS, and then fixed with 4% PFA at room temperature.

[0096] Afterwards, in order to visually confirm differentiation, 1 mL of a solution prepared by dissolving 0.2 g oil red O powder in 40 mL isopropanol and filtering through a 0.22 μm filter was added, reacted at room temperature for 15 minutes, and washed 5 times with DW. As shown in Fig. 5, adipogenic differentiation was confirmed using a microscope (Olympus).

[0097]

[0098] [Example 5]

[0099] Confirmation of chondrogenic differentiation potential of isolated mesenchymal stem cells (hMSCs)

[0100]

[0101] In order to confirm the chondrocyte differentiation ability, 9.5x10 4The cells were placed in a 6-well plate and cultured in a culture medium containing 1X insulin transferrin selenium premix (ITS), 50 ng / mL ascorbic acid, 40 μg / mL L-proline, 100 nM dexamethasone, 10% FBS, 1X AA in α MEM, and 10 ng / mL transforming growth factor (TGF-β3). The culture medium was then added and cultured in a 5% CO2 incubator at 37°C for 21 days. Afterwards, the culture medium from the plate where differentiation was complete was removed, and the cells were fixed at room temperature using 4% PFA.

[0102] Once fixed, the cells were washed with DPBS and placed in OCT compound and frozen in an ultra-low temperature freezer (-80°C) for one day. The frozen cells were sectioned into 8 μm thick sections using a cryocut microtome and washed with deionized water. A 1% alcian blue solution prepared using alcian blue reagent was added to the sections and stained at room temperature for 30 minutes. Then, the sections were washed with a 0.1N HCl solution and then washed with deionized water. As shown in Figure 5, differentiation into chondrocytes (chondrogenic differentiation) was confirmed using a microscope (Olympus).

[0103] As a result of confirming differentiation ability through the above Examples 3 to 5, it was confirmed that the purity of cells isolated from human fat by the technology of the present invention was very high, and it was confirmed that they had characteristics as stem cells even during long-term culture.

[0104]

[0105] [Example 6]

[0106] Preliminary research for the production of organoid-tissue modules

[0107]

[0108] Typically, organoids require long-term culture to produce, and as their size increases, the supply of oxygen and nutrients to the cells located at the center of the spherical organoids becomes limited, increasing the likelihood of cell death. Therefore, we sought to identify conditions for generating cup-shaped organoid-tissue modules to ensure a smooth supply of oxygen and nutrients to the center. After identifying the conditions for generating organoid-tissue modules, we aimed to provide a differentiation environment during the generation process of the organoid-tissue modules to rapidly generate organoids that grew to several millimeters in size.

[0109] Using the hMSCs manufactured and confirmed in the above examples, spheroids of various sizes were produced for constructing organoid-tissue modules. 10,000 or 15,000 hMSCs were placed in each well of a 96-well flat or U-bottom plate and centrifuged at 500*?*g for 5 minutes to induce forced aggregation. The cells were cultured to form randomly aggregated cell aggregates, which were then cultured to produce spheroids of various sizes.

[0110] Large and small hMSC spheroids, 50–500 μm in diameter, were formed in each well, and all spheroids formed in a 96-well plate were collected. The supernatant was removed by centrifugation, resuspended in 200 μl of medium, and transferred to a well of an ultra-low attachment 96-well plate. Self-assembly was induced by placing the plate in a 37°C incubator.

[0111] The generated spheroids ranged in size depending on the condition of the bottom of the 96-well plate used (flat bottom or round bottom). As shown in Fig. 6, there were wells in which self-assembly did not occur, and as shown in Fig. 7, there were wells containing organoid-tissue modules with a unique structure of self-assembly and a concave groove in the center. The unique self-assembled cup-shaped structure with a diameter of 2 to 4 mm was named an organoid-tissue module.

[0112]

[0113] [Example 7]

[0114] Image analysis of spheroid organoid-tissue module generation

[0115]

[0116] Spheroids were mixed and transferred to a plate with a designated area (e.g., a 96-well plate), and time-lapse images were taken for 72 hours from the time point (0 hour) when the spheroids settled to the bottom of the well. Each time-lapse image was combined to create a video of the spheroid self-assembly process, which was then analyzed. As a result, as shown in Figure 8, it was confirmed that the spheroids moved dynamically and went through the initiation stage, condensation stage, and lifting and folding stage to create cup-shaped organoid-tissue modules.

[0117] The point at which the spheroids sank to the bottom of the well (0 h) was designated as the initiation phase, the phase in which each spheroid moved toward the center and aggregated was designated as the condensation phase, and the phase in which a cup shape was formed was designated as the lifting and folding phase. In the initiation phase, each spheroid had a distinct boundary, and in the condensation phase, the spheroids moved toward the center, fused with neighboring spheroids, and continuously contracted toward the core. In the lifting and folding phase, the edges of the organoid-tissue modules were lifted and folded upward against gravity, creating a cup-shaped organoid-tissue module.

[0118] As shown in Figure 9, when large and small spheroids aggregate, we observed that small spheroids were attracted to and aggregated with large spheroids. These results indicate that spheroid size and its size ratio are important for inducing self-organization for organoid-tissue modules.

[0119]

[0120] [Example 8]

[0121] Size analysis of spheroids for the production of organoid-tissue modules

[0122]

[0123] To determine the spheroid mixing conditions for producing organoid-tissue modules, images of the initiation stage from wells where organoid-tissue module production was successful and wells where it failed were analyzed.

[0124] Using ImageJ, the diameters of measurable spheroids at the initiation stage were obtained, and spheroids belonging to each size range were classified as shown in Table 1 and Figure 10.

[0125]

[0126] Spheroid diameter (μm)Average spheroid diameter (μm)d1100 or less80d2100 ~ 200140d3200 ~ 300250d4300 ~ 400330d5400 ~ 500430

[0127]

[0128] The average diameter of spheroids in each size range was 80 μm for less than 100 μm, 140 μm for 100 to 200 μm, 250 μm for 200 to 300 μm, 330 μm for 300 to 400 μm, and 430 μm for 400 to 500 μm.

[0129] When the spheroid sizes of the wells in which the organoid-tissue modules were generated were analyzed, as shown in Figure 11, the average diameter of small spheroids with a diameter of 200 μm or less was 110 μm, and the average diameter of large spheroids with a diameter of more than 200 μm was 270 μm.

[0130]

[0131] [Example 9]

[0132] Analysis of the number distribution of spheroids according to size for the production of organoid-tissue modules.

[0133]

[0134] The results of analyzing the number of spheroids of each size that constituted a well (Success) in which organoid-tissue module creation was successful are shown in Table 2 and Figure 12 below.

[0135]

[0136] Spheroid diameter (μm) Number (%) d1100 or less 31 d2100 ~ 200 51 d3200 ~ 300 12 d4300 ~ 400 5 d5400 ~ 500 1

[0137] The results of analyzing the number of spheroids of various sizes that constituted wells (Failures) that were not produced as organoid-tissue modules are shown in Table 3 and Figure 12 below.

[0138]

[0139] Spheroid diameter (μm) Number (%) d1100 or less 12 d2100 ~ 200 11 d3200 ~ 300 6 1 d4300 ~ 400 16 d5400 ~ 5000

[0140] As shown in Tables 2 and 3 above, when the mixed spheroid diameters in the organoid-tissue module initiation step were of various sizes, from 50 to 500 μm, it was confirmed that when 23% of the spheroids were less than 200 μm, the organoid-tissue module was not produced, and when 82% were produced, the organoid-tissue module was produced.

[0141] Additionally, it was confirmed that organoid-tissue modules were not produced when 77% of spheroids had a diameter exceeding 200 μm, but were produced when 18% did.

[0142] Additionally, it was confirmed that organoid-tissue modules were produced when the number of spheroids with a diameter of 200 μm or less was greater than the number of spheroids with a diameter of more than 200 μm.

[0143]

[0144] [Example 10]

[0145] Analysis of space occupancy of spheroids for the production of organoid-tissue modules

[0146]

[0147] To determine the conditions for producing organoid-tissue modules, the occupied space and residual space of spheroids according to size were analyzed.

[0148] The results of analyzing the space occupied by the size of the spheroids that constituted the wells (Success) in which organoid-tissue module creation was successful are shown in Table 4 and Figure 13 below. The space occupied is expressed as a percentage of the sum of the spaces occupied by spheroids belonging to the following size ranges relative to the sum of the spaces occupied by all spheroids.

[0149] The space occupied by an individual spheroid is given by the formula π x r from the radius (r) derived from ImageJ analysis.2 It was calculated using .

[0150]

[0151] Spheroid diameter (μm)Average space occupied (%)d1100 or less8d2100 ~ 20040d3200 ~ 30029d4300 ~ 40020d5400 ~ 5003

[0152]

[0153] The results of analyzing the space occupied by spheroids according to spheroid size that constitute wells (Failures) that were not produced as organoid-tissue modules are shown in Table 5 and Figure 13 below.

[0154]

[0155] Spheroid diameter (μm)Average space occupied (%)d1100 or less1d2100 ~ 2005d3200 ~ 30069d4300 ~ 40025d5400 ~ 5000

[0156] As shown in Tables 4 and 5 above, when the mixed spheroid diameters in the organoid-tissue module initiation step were of various sizes, from 50 to 500 μm, it was confirmed that when spheroids of 200 μm or less accounted for 6% of the space occupied by the entire spheroids, the organoid-tissue module was not produced, but was produced when it accounted for 48%.

[0157] Additionally, it was confirmed that organoid-tissue modules were not produced when spheroids with a diameter exceeding 200 μm accounted for 94% of the space occupied by the entire spheroids, but were produced when they accounted for 52%.

[0158] Assuming that the bottom area of ​​the well is 100%, the empty space (Remaining Space) excluding the space occupied by the spheroid was additionally analyzed using ImageJ software, and the results are shown in Fig. 14 and Table 6.

[0159] As shown in Figure 14, Table 6 and Table 7, when the organoid-tissue module is manufactured, it was confirmed that the area of ​​empty space relative to the total area was 5 to 40%.

[0160] Finally, in order to manufacture organoid-tissue modules, it can be seen that the area of ​​empty space is 5 to 40%, preferably 10 to 35%, and more preferably 15 to 30%.

[0161]

[0162] The percentage of the area not occupied by spheroids among the successfully cultured areas (%) 5.89 56 42 6.08 8 49 6.72 21 33 11.50 66 14.49 116 15.20 74 516.42 9 16.42 9 16.78 69 7 19.28 48 121.47 22.57 24 126.86 09 8 26.86 127.18 22 7.18 22 7.90 8 28.01 8 28.73 429.21 18 9 29.21 23 0.06 59 43 0.06 6 34.50 134.57 5 34.57 5 Mean 22.60 023 Standard deviation 9.83 80 78

[0163]

[0164] The percentage of the area not occupied by spheroids among the failed culture areas (%) 1.6897171.8641982.3141772.8008893.3151513.6365643.78349642.5367844.2815951.5730952.558.662.3

[0165]

[0166] [Example 11]

[0167] Bio-kinematic analysis of organoid-tissue module production

[0168]

[0169] To confirm the self-assembly process of the organoid-tissue module, bio-kinematic analysis was performed as follows.

[0170] During the formation of organoid-tissue modules, the movement of spheroids was videotaped, and the spatiotemporal distributions of spheroids, including their velocity, trajectory, linearity, and coherence, were analyzed and calculated based on the videos. Images captured over time were processed using the Image J program and a MATLAB code based on the particle image velocimetry (PIV) algorithm to calculate spheroid motility within a confined space during the fabrication of organoid-tissue modules.

[0171] As shown in Figure 15, typical characteristics of spheroid movement were observed during the initiation, condensation, lifting, and folding stages of organoid-tissue module production. The spheroids' average velocity fluctuated every 12 hours, likely due to the culture medium exchange performed every 12 hours. Therefore, changes in motility due to medium exchange were excluded from the analysis.

[0172] In the initiation phase, each spheroid exhibited irregular and different motility (0-1.5 μm / min).

[0173] During the condensation phase, the movement of the central part of the organoid-tissue module was relatively static, while the spheroids in the boundary region still showed dynamic motility.

[0174] During the lifting and folding stages, most spheroid movements were reduced and stabilized, with only slight repetitive movements observed in the boundary region.

[0175] Furthermore, as shown in Figure 16, analysis of the movement distance (path length) of spheroids revealed that the organoid-tissue module boundary region during the condensation phase exhibited linear movement, whereas spheroids in the central region exhibited torsional movement. During the lifting and folding phases, little movement of spheroids was observed in the boundary region.

[0176] Trajectory analysis in Figure 17 revealed that spheroids exhibited random movement during the initiation phase, but during the condensation phase, spheroids in the boundary region were observed to move linearly toward the center. Interestingly, spheroids in the folding region exhibited longer trajectories and higher linearity than those in the center. This movement is a phenomenon typically observed when aggregates form a stable structure, indicating that the organoid-tissue module in the lifting-folding phase has transitioned into a structurally stable structure.

[0177] Additionally, analysis of phenotypic parameters such as circularity revealed that, as shown in Figure 18, after mixing spheroids and culturing for 24 hours, the circularity of the organoid-tissue modules temporarily decreased due to spheroid motility, but after an additional 18 hours of culturing, it approached 1.0, indicating a circle with the same diameter in all directions. These results imply that organoid-tissue modules with irregular structures began to reorganize into regular structures within 24 hours.

[0178] Additionally, as shown in Fig. 18, biokinetic and morphological analyses show that the organoid-tissue module self-structures at each stage: initiation (0 hours), condensation (4.3 hours), and lifting and folding (39 hours).

[0179]

[0180] [Example 12]

[0181] Fabrication of organoid-tissue modules using optimized conditions

[0182]

[0183] From the experimental results of Examples 8 to 11 above, it was confirmed that the mixing ratio of spheroids having a diameter of 200 μm or less and spheroids having a diameter of more than 200 μm, the space occupancy ratio of spheroids having a diameter of 200 μm or less and spheroids having a diameter of more than 200 μm, and the area of ​​empty space relative to the space in which organoid-tissue modules are cultured are directly related to the production of organoid-tissue modules.

[0184] Therefore, experiments were conducted under various conditions to verify the above conditions.

[0185] Each microwell of the AggreWell plate was filled with 100, 500, 1000, 3000, and 5000 cells, and the culture medium used was DMEM containing 40 μg / ml L-proline, 100 μg / ml sodium pyruvate, 50 μg / ml L-ascorbic acid 2-phosphate, 1xITS, and 1xAA.

[0186] The results of culturing in Aggrewell are shown in Fig. 19. Spheroids composed of 500 cells with an average diameter of 200 μm or less were selected, and spheroids composed of 3,000 cells were selected for spheroids with an average diameter of more than 200 μm. Spheroids composed of 500 cells were named 0.5K spheroids, and spheroids composed of 3,000 cells were named 3K spheroids.

[0187] As described in Example 10 above, the two sizes of 0.5K and 3K spheroids obtained above were mixed and arranged in different ratios in an ultra-low attachment 96-well plate so that the empty area of ​​the total culture area was approximately 20%.

[0188] First, when the 0.5K spheroids were increased to 10%, 30%, and 50%, self-assembly did not occur. On the other hand, when 0.5K spheroids were mixed at 60% or more and 3K spheroids at 40% or less among 0.5K and 3K spheroids, it was confirmed that organoid-tissue modules were formed through self-assembly of spheroids, as shown in Fig. 20. Therefore, it can be seen that organoid-tissue modules are produced when spheroids with different diameters are mixed and cultured, and when the number of spheroids with a diameter of 200 μm or less is greater than the number of spheroids with a diameter of over 200 μm, organoid-tissue modules are well produced.

[0189] In order to investigate the effect of empty space on the formation of organoid-tissue modules, the mixing ratios of 0.5K spheroids and 3K spheroids were fixed at 90% and 10%, respectively, and the empty culture areas not occupied by spheroids were mixed and arranged to be 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, and less than 10%, respectively, as shown in Fig. 21. When the empty area was greater than 50%, spheroid self-assembly did not occur well, and when it was 40% or less, it was confirmed that organoid-tissue modules were well formed by spheroid self-assembly.

[0190] In another example, the empty space area was adjusted to 20% of the total culture area, and then spheroid self-organization was induced through culture to create organoid-tissue modules. As shown in Figure 22, organoid-tissue modules were generated through this self-assembly process, and it was confirmed that the cup-shaped structure was maintained even after 7 days of culture.

[0191] In addition, during the generation of organoid-tissue modules, spheroids fused and condensed with adjacent spheroids to form large structures. When spheroids fused to form organoid-tissue modules, the cells constituting the spheroids did not mix evenly when different spheroids fused, but rather remained in the original spheroids, as shown in Fig. 23, which was confirmed through the stained spheroid fusion process. After epifluorescence staining, the cup shape of the organoid-tissue modules was confirmed using a confocal microscope, as shown in Fig. 24. The average diameter of the organoid-tissue modules was approximately 2 to 4 mm (10 to 35% of the culture area), which was confirmed to be about half the size of the pineal gland (5-8 mm), the smallest organ in the human body.

[0192]

[0193] [Example 13]

[0194] Confirmation of hMSC stem cell characteristics in the fabricated organoid-tissue module

[0195]

[0196] To confirm whether the hMSCs constituting the fabricated organoid-tissue modules retained their stem cell characteristics, single cells were isolated from the organoid-tissue modules and their expression of stem cell markers and differentiation potential were examined. As shown in Figure 25, it was confirmed that the cells constituting the organoid-tissue modules expressed stem cell markers and differentiated into adipocytes, osteocytes, and chondrocytes, maintaining their stem cell characteristics.

[0197]

[0198] [Example 14]

[0199] Confirmation of apoptosis resistance of fabricated organoid-tissue modules

[0200]

[0201] To determine whether the fabricated organoid-tissue modules were more resistant to apoptosis than spherical cell aggregates, spherical aggregates and organoid-tissue modules composed of the same number of cells were fabricated. Spherical cell aggregates were prepared by placing cells in a U-bottom plate, centrifuging at 500 × g for 5 minutes, and inducing aggregation in a 37°C incubator. The cells were cultured for a total of 6 days under the same conditions as those for the organoid-tissue modules. In the case of the spherical cell aggregates, many dead cell fragments were present around the spheroids due to apoptosis, but as shown in Figure 26, relatively few dead cell fragments were observed in the organoid-tissue modules. The organoid-tissue modules and spherical cell aggregates were fixed in 4% PFA for one day and embedded in paraffin blocks. Slides were prepared at 4 μm thickness, deparaffinized, and treated with Proteinase K to dissolve intratissue proteins. Endogenous peroxidase was removed by treatment with 3% hydrogen peroxide (H2O2), and TUNEL (Terminal Deoxynucleotidyl Transferase dUTP Nick end Labeling) staining was performed using the ApoTag Peroxidase In Situ Apoptosis Detection Kit (Millipore). After counterstaining the nucleus with methyl green, images were acquired. As shown in Figure 26, no increased apoptosis was observed in the center of the organoid-tissue module compared to the periphery. However, in the center of the spherical cell aggregates, there were many dead cells stained with TUNEL, and empty spaces were created due to necrosis. From this, it is believed that the organoid-tissue module has a cup-shaped structural feature with a concave center, which ensures a smooth supply of nutrients and oxygen, and it is judged to have a technical advantage that can overcome the disadvantage of increasing central apoptosis as the size increases.

[0202]

[0203] [Example 15]

[0204] Confirmation of the possibility of differentiation into chondrocytes of the organoid-tissue module produced by confirming the expression of type 2 collagen.

[0205]

[0206] The hMSCs used in the present invention are stem cells that can differentiate into chondrocytes, and thus have been used as a promising cell source in cartilage tissue engineering (Somoza et al., 2014). To confirm the differentiation potential of the fabricated organoid-tissue module into chondrocytes, TGF-β3 was treated to induce differentiation of the organoid-tissue module into chondrocytes. The samples were recovered, fixed in 4% PFA for approximately 3 days, and immunohistochemistry (IHC) staining was performed for histological analysis.

[0207] For this purpose, fixed samples were embedded in paraffin blocks and slides were made with a thickness of 4 μm. The slides were deparaffinized in histo-clear for 30 minutes, hydrated from 100% ethanol to 70% ethanol, and washed with PBS. Afterwards, the slides were blocked with a PBS solution containing 0.3% bovine serum albumin (BSA) at room temperature for 1 hour, and then the primary antibody for type 2 collagen was diluted at an appropriate concentration in the same solution and left to stand at 4°C for more than 12 hours. After the resting, the slides were washed with PBS again, and the secondary antibody was diluted at an appropriate concentration in the blocking solution, left to stand at 37°C for 1 hour, washed with PBS, and reacted with DAB to develop color.

[0208] The above experimental results are shown in Fig. 27, and it was confirmed that type 2 collagen was mainly expressed in cells of spherical units corresponding to large spheroids.

[0209]

[0210] [Example 16]

[0211] Confirmation of the potential for differentiation into chondrocytes of organoid-tissue modules produced through aggrecan identification

[0212]

[0213] In order to confirm Aggrecan, a marker of chondrocyte differentiation, the spheroids were made transparent by performing a 3D clearing process according to the method of Korean Patent No. 10-2170076 (Method for producing decellularized tissue using hydrogel polymer and decellularized tissue produced therefrom), and then the expression of Aggrecan was examined in 3D using an antibody.

[0214] For this purpose, the produced organoid-tissue modules were fixed in 4% PFA for 1 week, washed with 0.1% triton-X dissolved in PBS, and then blocked for at least 8 hours at room temperature using a solution of 6% BSA, 0.2% triton X-100, and 0.01% sodium azide dissolved in PBS. After that, the aggrecan antibody was diluted to an appropriate concentration in the blocking solution, dispensed into the organoid-tissue modules, and reacted for 2 days at room temperature. Washing was performed with the previously used washing solution, and the secondary antibody and hoechest were diluted to an appropriate concentration in the blocking solution, dispensed into the spheroids, and reacted for 2 days at room temperature. After the antibody reaction was completed through the washing process, the transparent process was performed using a solution of 25% urea and 65% sucrose dissolved in water.

[0215] The results of the above experiment are shown in Figure 28, and it was confirmed that the expression of aggrecan was highest at the edge of the organoid-tissue module.

[0216]

[0217] [Example 17]

[0218] Quantitative comparative analysis of chondrogenic differentiation through glycosaminoglycans

[0219]

[0220] To quantitatively compare and analyze cartilage differentiation through glycosaminoglycan (GAG), an important extracellular matrix of cartilage, a GAG assay was performed.

[0221] To this end, a papain solution was prepared by dissolving 200 mM sodium phosphate, 100 mM sodium acetate, 10 mM ethylenediamine tetraacetic acid (EDTA), and 5 mM L-cysteine ​​and adjusting the pH to 6.4. 7.8 μL of papain was added to the solution, and the sample was reacted in a constant-temperature water bath at 65°C for 18 hours. After 18 hours, the solution was centrifuged at 10,000 g for 10 minutes, and the GAG ​​content was measured according to the instructions of the sulfate glycosaminoglycan assay kit.

[0222] The absorbance of the sample was measured at 656 nm using a microplate reader, and the total DNA amount was quantified using a pico-green dsDNA assay kit to normalize the measurement results.

[0223] The results of the above experiment are shown in Fig. 29, and it was confirmed that the GAG ​​content was significantly increased in the organoid-tissue module compared to single cells.

[0224]

[0225] [Example 18]

[0226] Histological analysis of chondrogenic differentiation-induced organoid-tissue modules using various staining techniques.

[0227]

[0228] To confirm the results of immunohistological staining, organoid-tissue module samples were embedded in paraffin blocks and sectioned at 4 μm thickness to produce slides. After deparaffinization using the same method as above, they were stained using a hematoxylin & eosin (H&E) solution. Synthetic collagen within the organoid-tissue modules was detected using a Trichrome III Blue Staining Kit, and GAG expression was visualized using a Safranin-O / fast green kit.

[0229] The results of the above experiment are shown in Fig. 30. Masson's trichrome staining results showed that the entire organoid was stained blue due to collagen synthesis, and Safranin-O staining results showed that red-stained GAG was expressed in all locations of the organoid-tissue module. Therefore, it was confirmed that the organoid-tissue module was differentiated into chondrocyte organoids by a chondrogenic differentiation factor such as TGF-β3.

[0230]

[0231] [Example 19]

[0232] Confirmation of the efficacy of organoid-tissue modules in a rabbit model of cartilage defects.

[0233]

[0234] To investigate the cartilage regeneration efficacy of organoid-tissue modules in a cartilage defect osteoarthritis (OA) model, a cartilage defect model with full-thickness cartilage removal was created in the knee of adult New Zealand white rabbits, and organoid-tissue modules were transplanted into the defect site. This experiment was approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital (SNUH-IACUC No. 18-0171-S1A0), and animals were maintained in a facility assessed and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) in accordance with the 8th edition of the Guide for the Care and Use of Laboratory Animals of the National Research Corporation (NRC).

[0235] Rabbits were anesthetized by intramuscular injection with a mixture of 5 mg / kg xylazine and 15 mg / kg Zoletil, and a cartilage defect measuring 3 mm in diameter and 3 mm in depth was induced in the knee joint using sterile surgical instruments. In the organoid-tissue module transplantation group, the organoid-tissue module was inserted and sutured, and antibiotics and analgesics were administered subcutaneously with 0.3 mL Metacam and 1 mL Cefazolin for 3 days after surgery. The animals were sacrificed at 12 or 14 weeks after surgery, and the knees were excised for micro-computed tomography (Micro-CT) prior to histological evaluation.

[0236] After the experiment, micro-CT images of the rabbit cartilage were taken, and as shown in Figure 31, it was confirmed that all the defective areas were completely filled. In addition, paraffin sections were prepared using rabbit knee cartilage tissue and H&E staining was performed, and the formation of the epiphyseal plate structure was confirmed to be increased in the defective cartilage, and the morphology of extensive extracellular matrix and osteophytes was clearly confirmed at the transplantation site of the organoid-tissue module.

[0237] In addition, as a result of confirming the relevant area through safranin-O staining, formation of hyaluronic cartilage was confirmed in the organoid-tissue module transplantation group, as shown in Figure 31.

[0238] Through the above experiments, we confirmed that the cartilage generated 12 weeks after transplantation of organoid-tissue modules into a CD / OA rabbit model was thicker than the existing surrounding cartilage in the rabbit, and that the organoid-tissue modules completely fused with the damaged cartilage. Ultimately, we were able to demonstrate that millimeter-sized organoid-tissue modules exhibit excellent regenerative effects in the CD / OA model.

Claims

1. Method for manufacturing organoid-tissue modules by mixing and culturing spheroids of different diameters.

2. A method for producing an organoid-tissue module, characterized in that the spheroid has a diameter of 10 to 1,000 μm in the first paragraph.

3. A method for producing an organoid-tissue module, characterized in that the spheroid in the first paragraph has a diameter of 50 to 500 μm.

4. A method for manufacturing an organoid-tissue module, characterized in that spheroids having a diameter of 200 μm or less in the first paragraph account for 60% or more of the total spheroids.

5. A method for manufacturing an organoid-tissue module, characterized in that spheroids having a diameter of 200 μm or less in the first paragraph account for 70% or more of the total spheroids.

6. A method for manufacturing an organoid-tissue module, characterized in that spheroids having a diameter of 200 μm or less in the first paragraph account for 80% or more of the total spheroids.

7. A method for producing an organoid-tissue module, characterized in that, in the first paragraph, spheroids having a diameter exceeding 200 μm account for 40% or less of the total spheroids.

8. A method for producing an organoid-tissue module, characterized in that, in the first paragraph, spheroids having a diameter exceeding 200 μm account for 30% or less of the total spheroids.

9. A method for producing an organoid-tissue module, characterized in that, in the first paragraph, spheroids having a diameter exceeding 200 μm account for 20% or less of the total spheroids.

10. A method for producing an organoid-tissue module, characterized in that the number of spheroids having a diameter of 200 μm or less in the first paragraph is greater than the number of spheroids having a diameter of more than 200 μm.

11. A method for manufacturing an organoid-tissue module, characterized in that the space not occupied by spheroids in the first paragraph is 5 to 40% of the total space for culturing spheroids.

12. A method for manufacturing an organoid-tissue module, characterized in that the space not occupied by spheroids in the first paragraph is 10 to 35% of the total space for culturing spheroids.

13. A method for manufacturing an organoid-tissue module, characterized in that the space not occupied by spheroids in the first paragraph is 15 to 30% of the total space for culturing spheroids.

14. A method for producing an organoid-tissue module, characterized in that the tissue module occupies 10 to 35% of the culture area in the first paragraph.

15. A method for manufacturing an organoid-tissue module, characterized in that the tissue module in the first paragraph has a diameter of about 2 to 4 mm.

16. A method for producing an organoid-tissue module, characterized in that the spheroid in the first paragraph is obtained by culturing stem cells or undifferentiated cells.

17. A method for producing an organoid-tissue module, characterized in that the stem cells or undifferentiated cells in paragraph 16 are selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, adult stem cells, and mesenchymal stem cells.

18. A method for producing an organoid-tissue module, characterized in that the stem cells in claim 17 are human adipose-derived mesenchymal stem cells (hMSCs).

19. A method for manufacturing an organoid-tissue module, characterized in that the organoid-tissue module in the first paragraph has a cup-shaped shape.

20. A method for manufacturing an organoid-tissue module, characterized in that the method according to claim 1 does not include a scaffold or an artificial material.

21. An organoid-tissue module manufactured by a manufacturing method according to any one of claims 1 to 20.

22. A pharmaceutical composition for preventing or treating cartilage disease, comprising the organoid-tissue module of Article 21.